Valrubicin

Brand name: Valstar

E

Score E — Unlikely Hepatotoxin

Despite extensive use, there is no convincing evidence that this drug causes liver injury.

Single case reports may have been published, but they were largely unconvincing. The agent is not believed or is unlikely to cause liver injury.

Primary class Antineoplastic
Secondary class Solid tumors
FDA approval 1998
Search another medication

No article link available. Search directly at livertox.nih.gov.